男性激素受体阳性乳腺癌辅助内分泌治疗的使用与疗效
男性接受辅助内分泌治疗的比例低于女性(67.3% vs 79.0%),但倾向评分加权分析显示,男性使用辅助内分泌治疗与总生存改善相关(HR 0.70,95%CI 0.63-0.77,P<.001)。
要点
- 男性激素受体阳性乳腺癌患者辅助内分泌治疗使用率低于女性。
- 学术机构治疗、接受辅助放疗或化疗与男性使用内分泌治疗相关。
- 男性使用辅助内分泌治疗与总生存改善相关(HR 0.70)。
核心结论
- 男性激素受体阳性乳腺癌患者辅助内分泌治疗存在性别差异性的使用不足,尽管该治疗与总生存改善相关。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2004至2014年数据。
主要发现
- 男性激素受体阳性比例高于女性(94.0% vs 84.3%,P<.001)。
- 符合条件男性接受辅助内分泌治疗比例低于女性(67.3% vs 79.0%;OR 0.61,95%CI 0.58-0.63;P<.001)。
- 男性在学术机构治疗(OR 1.13,95%CI 1.02-1.25;P=.02)、接受辅助放疗(OR 2.83,95%CI 2.55-3.15;P<.001)或化疗(OR 1.20,95%CI 1.07-1.34;P<.001)与辅助内分泌治疗使用显著相关。
- 倾向评分加权分析显示,男性使用辅助内分泌治疗相比未使用与总生存改善相关(HR 0.70,95%CI 0.63-0.77;P<.001)。
临床怎么用
- 对男性激素受体阳性乳腺癌患者,应评估并考虑辅助内分泌治疗以改善生存。
- 关注男性患者辅助内分泌治疗使用不足的问题,尤其在非学术机构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although adjuvant endocrine therapy confers a survival benefit among females with hormone receptor (HR)-positive breast cancer, the effectiveness of this treatment among males with HR-positive breast cancer has not been rigorously investigated. OBJECTIVE: To investigate trends, patterns of use, and effectiveness of adjuvant endocrine therapy among men with HR-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified patients in the National Cancer Database with breast cancer who had received treatment from 2004 through 2014. Inclusion criteria for the primary study cohort were males at least 18 years old with nonmetastatic HR-positive invasive breast cancer who underwent surgery with or without adjuvant endocrine therapy. A cohort of female patients was also identified using the same inclusion criteria for comparative analyses by sex. Data analysis was conducted from October 1, 2017, to December 15, 2017. EXPOSURES: Receipt of adjuvant endocrine therapy. MAIN OUTCOMES AND MEASURES: Patterns of adjuvant endocrine therapy use were assessed using multivariable logistic regression analyses. Association between adjuvant endocrine therapy use and overall survival was assessed using propensity score-weighted multivariable Cox regression models. RESULTS: The primary study cohort comprised 10 173 men with HR-positive breast cancer (mean [interquartile range] age, 66 [57-75] years). The comparative cohort comprised 961 676 women with HR-positive breast cancer (mean [interquartile range] age, 62 [52-72] years). The median follow-up for the male cohort was 49.6 months (range, 0.1-142.5 months). Men presented more frequently than women with HR-positive disease (94.0% vs 84.3%, P < .001). However, eligible men were less likely than women to receive adjuvant endocrine therapy (67.3% vs 79.0%; OR, 0.61; 95% CI, 0.58-0.63; P < .001). Treatment at academic facilities (odds ratio, 1.13; 95% CI, 1.02-1.25; P = .02) and receipt of adjuvant radiotherapy (odds ratio, 2.83; 95% CI, 2.55-3.15; P < .001) or chemotherapy (odds ratio, 1.20; 95% CI, 1.07-1.34; P < .001) were statistically significantly associated with adjuvant endocrine therapy use in men. A propensity score-weighted analysis indicated that relative to no use, adjuvant endocrine therapy use in men was associated with improved overall survival (hazard ratio, 0.70; 95% CI, 0.63-0.77; P < .001). CONCLUSIONS AND RELEVANCE: There is a sex disparate underuse of adjuvant endocrine therapy among men with HR-positive breast cancer despite the use of this treatment being associated with improved overall survival. Further research and interventions may be warranted to bridge gaps in care in this population.
引用
- Venigalla S, Carmona R, Guttmann DM, et al. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men. JAMA Oncol. 2018. PMID: 29800030. doi:10.1001/jamaoncol.2018.1114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。